Shares of Evotec SE (NASDAQ:EVO - Get Free Report) rose 3.4% on Tuesday . The company traded as high as $3.18 and last traded at $3.07. Approximately 32,311 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 138,971 shares. The stock had previously closed at $2.97.
Evotec Trading Up 3.9 %
The firm's 50-day moving average is $3.81 and its two-hundred day moving average is $4.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Trading of Evotec
A number of large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in Evotec in the fourth quarter worth about $27,000. CSS LLC IL bought a new stake in shares of Evotec in the 4th quarter valued at approximately $50,000. Bank of America Corp DE lifted its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in shares of Evotec in the 4th quarter worth approximately $166,000. Finally, DCF Advisers LLC increased its position in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the last quarter. 5.81% of the stock is currently owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
